Neurimmune has agreed royalty financing worth up to USD 425 million with Royalty Pharma. The Schlieren biotechnology company receives USD 125 million upfront and another USD 125 million in the first quarter of 2027, while USD 175 million depends on clinical and regulatory milestones. In return, Royalty Pharma receives a 3% to 4% royalty on worldwide net sales of cliramitug.
The proceeds will support Neurimmune's internal research and development without issuing new equity. Cliramitug is an investigational antibody intended to remove amyloid deposits from the hearts of patients with transthyretin amyloid cardiomyopathy; Alexion, AstraZeneca Rare Disease, is responsible for its development and is evaluating it in a Phase 3 trial. Neurimmune retains substantial royalty and milestone interests.
